1. A pharmaceutical composition for oral administration containing alisporivir in an amount of from about 15% to about 20% by weight of the composition and water in an amount of from about 2% to about 15% by weight of the composition. The pharmaceutical composition of claim 1, comprising a lipophilic component, a surfactant and a hydrophilic component, and wherein the water is contained in an amount of from about 4% to about 15% by weight of the composition. A composition according to claim 1 or 2, wherein the water is contained in an amount of about 4% to about 5% by weight of the composition. A composition according to claim 2, wherein alisporivir is contained in an amount of from about 19% to about 20% by weight of the composition. The pharmaceutical composition of claim 1 in the form of a preconcentrate for oral administration, comprising: 1) alisporivir in an amount of about 15% to about 20% by weight of the composition, 2) a lipophilic component, 3) a surfactant, 4) polyethylene glycol and 5) water in an amount of from about 2% to about 15% by weight of the composition. The pharmaceutical composition of claim 1 in the form of a preconcentrate for oral administration, comprising: 1) alisporivir in an amount of from about 19% to about 20% by weight of the composition, 2) a lipophilic component, 3) a surfactant, 4) ethanol and 5) water in an amount of from about 4% to about 5% by weight of the composition. The composition of claim 2, wherein the hydrophilic component is selected from the group consisting of ethanol, polyethylene glycol, triethyl citrate, diethylene glycol monoethyl ether and propylene glycol, preferably selected from the group consisting of ethanol�1. Фармацевтическая композиция для перорального введения, содержащая алиспоривир в количестве приблизительно от 15% приблизительно до 20% по массе композиции и воду в количестве приблизительно от 2% приблизительно до 15% по массе композиции.2. Фармацевтическая композиция по п. 1, содержащая липофильный
